Indivior PLC (INDVN.MX)
| Previous close | 0.0000 |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | N/A - N/A |
| 52-week range | undefined - undefined |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Why Indivior PLC (LON:INDV) Looks Like A Quality Company
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
PR NewswireIndivior Announces Q1 2024 Financial Results
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
- PR Newswire
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose. The study, "Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone", was published in the Journal of Clinical Pharmacology (Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers:
